« Return to News | Drug Sponsors

ITI, Takeda in collaboration

Thursday, March 3, 2011 02:40 PM

Intra-Cellular Therapies has entered into a preclinical discovery deal with Takeda to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors for cognitive impairment associated with schizophrenia and a variety of psychiatric and neurological diseases, according to FierceBiotech.

ITI has retained the option to co-promote with Takeda in the U.S., and will be eligible for $500 million in development milestones plus another $250 million in sales-based milestones, along with tiered royalty payments.

Takeda will be solely responsible for development, manufacturing and commercialization of PDE1 inhibitors. ITI's PDE1 inhibitors are orally-available, preclinical-stage compounds.

"We are able to enhance our central nervous system pipeline, one of our core therapeutic areas, through this collaboration," said Shigenori Ohkawa, chief scientific officer for Takeda. “We plan to accelerate our R&D activities for this compound in an effort to bring this novel medicine to patients as quickly as possible."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.